ArticleBalkan journal of medical genetics : BJMG2025
Molecular and Immunohistochemical Biomarkers in Colorectal Carcinoma - A Single Center Study.
Article in Balkan journal of medical genetics : BJMG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Colorectal cancer is the third most common malignancy in the world and among the most frequent causes of cancer-related death. Our study aimed to evaluate the molecular profile of the patients diagnosed with colorectal carcinoma at Clinical Hospital Acibadem-Sistina in Skopje. Materials and methods: This study is retrospective-prospective, conducted at the Department of histopathology and cytology, at Clinical Hospital Acibadem-Sistina in Skopje. Tissue samples from surgical material from 152 patients diagnosed with CRC were processed for molecular and immunohistochemical analysis. KRAS and BRAF mutations were analyzed, and MMR status was obtained. In 90 metastatic cases, evaluation of HER2 and PDL-1 expression was performed on a tissue microarray. Results: Among 152 analyzed patients diagnosed with colorectal carcinoma, the majority were males (98, 64.47%) compared to females (54, 35.53%). The mean age was 68.4±11.3 years; the median age was 70 years. KRAS/NRAS mutations were detected in 47(31%) of patients, BRAF mutations in 11(7%) patients, and mismatch repair gene deficiency (MMRd) was found in 15(10%) of patients. HER2 positive expression was present in 36(40%) of patients, and 17(19%) of patients showed PDL-1 expression. In the group of 17 PDL1-positive tumors, a cutoff of more than 1% positive tumor cells was detected in 10 cases, more than 10% tumor cells in 4 cases, and more than 50% tumor cells in 3 cases. From 36 HER2 positive cases, 32(32,5%) were with score 2+, and 4(4,4%) with score 3+. Conclusions: Continued research into molecular mechanisms and biomarkers holds the promise of further improving CRC outcomes through personalized and effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.